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Abstract
The use of neoadjuvant chemotherapy followed by tumor reduction surgery, also called interval debulking sur-
gery (IDS), is considered an alternative therapeutic regimen for selected patients with advanced stage epithelial
ovarian cancer (EOC). Although minimal residual disease has been proven to be a prognostic factor in traditional
cytoreduction for advanced stage EOC, predictive factors after IDS still remain unexplored. The aim of this study
was to determine the prognostic value of post-neoadjuvant histologic changes with clinical outcome. Three pathol-
ogists evaluated 67 cases for the following parameters: fibrosis, necrosis, residual tumor, and inflammation. The
Cohen's kappa statistic was used to measure agreement among pathologists. Univariate and multivariate Cox pro-
portional hazards models were used to determine the association between histologic parameters and recurrence-
free survival (RFS) and overall survival (OS). There was substantial to almost perfect agreement among the three
pathologists in all four histologic parameters (k ranged from 0.65 to 0.97). Fibrosis was associated with longer RFS
(P = 0.0257) with a median of 20 months for tumors with fibrosis (3+) versus 12 months for tumors with fibrosis
(1+, 2+) and longer OS (P = 0.0249) with a median of 51 months for tumors with fibrosis (3+) versus 32 months
for tumors with fibrosis (1+, 2+). Our results revealed that patients with tumors exhibiting fibrosis (1+, 2+), as
well as necrosis (0, 1+), had significant shorter RFS and OS (P = 0.059 and P = 0.0234, respectively). We suggest
that the assessment of fibrosis and necrosis should be implemented in pathologic evaluation and prospectively
validated in future studies.
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Introduction
Epithelial ovarian cancer (EOC) is the most common type of ovarian
cancer, representing 80% to 90% of all ovarian cancers. It is the lead-
ing cause of death in the United States in women diagnosed with
gynecologic malignancies with 21,990 new cases and 15,460 women
estimated to die of ovarian cancer in 2011 [1]. The high mortality rate
is mainly due to advanced stage disease at initial diagnosis. Primary
cytoreduction surgery followed by chemotherapy is considered the
standard of care for patients with advanced stage surface EOC [2].
There have been several debates about whether neoadjuvant chemo-
therapy followed by interval debulking surgery (IDS) is superior to
primary tumor reductive surgery. In fact, a recent randomized clinical
trial has shown that the survival rate after neoadjuvant platinum–
based chemotherapy followed by IDS is similar to the survival after
the standard approach of primary cytoreduction surgery followed by
chemotherapy in women with advanced stage (stage IIIC and stage
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IV) EOC [3]. Furthermore, the recent National Comprehensive
Cancer Network guidelines for 2012 recommended that physicians
should consider neoadjuvant chemotherapy with carboplatin and
paclitaxel, rather than immediate surgery, in selected patients. This
recommendation was supported by strong clinical data, indicating
that using this approach decreases surgical morbidity with equivalent
survival times [4].
The morphologic effects on ovarian carcinoma after neoadjuvant
chemotherapy have been described and consist of a wide range of
changes in both tumor cells and stroma. The changes in tumor cells
consist of nuclear and cytoplasmic alterations including nuclear
enlargement, hyperchromasia, chromatin clumping and smudg-
ing, eosinophilia, and vacuolization and foamy/clear cell changes.
The stromal alterations consist of dense fibrosis, inflammation,
foamy histiocytes, cholesterol clefts, necrosis, and dystrophic calci-
fications [5,6]. Similar morphologic effects of neoadjuvant chemo-
therapy or chemoradiation therapy in other organs such as pancreas,
breast, rectum, and esophagus have also been described in the litera-
ture [7–13].
In advanced stage EOC treated with standard cytoreduction fol-
lowed by chemotherapy, the best predictive factor for better disease
outcome is still defined by successful tumor reduction (residual dis-
ease ≤ 1 cm) [14–16]. However, the predictive factors for disease
outcome are still lacking for patients treated with the alternative
IDS. Therefore, the aims of this study are two-fold: 1) to assess spe-
cific, seemingly reproducible morphologic parameters such as per-
centage of residual tumor (RT), fibrosis, necrosis, and inflammation
on hematoxylin-eosin slides from patients with ovarian cancer treated
with neoadjuvant chemotherapy for advanced stage EOC and 2) to
determine whether each of these morphologic parameters or any of
their combinations might be helpful in predicting patient outcome.
Materials and Methods
Patient Population
After institution-specific institutional review board (IRB) approval,
patients with advanced stage EOC treated with neoadjuvant therapy
between January 2002 and December 2011 were retrospectively iden-
tified through the medical and pathology records at the University of
Southern California and the Oregon Health and Science University.
The initial diagnosis was made by core biopsy or cytology of the ascitic
Figure 1. An example of high-grade serous carcinoma case presenting with ≥50% RT (3+): (A) ×10, (B) ×20, and (C) ×60. A case of
ovary with RT of 6% to 50% (2+): (D) ×10, (E) ×20, and (F) ×60. A case of ovary with minimal RT of 0% to 5% (1+): (G) ×10, (H) ×20,
and (I) ×60.
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fluid. All patients had imaging studies and serum cancer antigen-125
levels. After diagnosis, the patient was given carboplatin (AUC 5) and
paclitaxel (175 mg/m2) for three or four cycles. The patients were then
reassessed with computerized tomography scanner (CT scan) and
sometimes with serum carcinoembryogenic antigen (CEA) levels. If
tumor burden was reduced, the patient underwent IDS, and another
three or four cycles was administered after surgery depending on the
disease burden intraoperatively. Hematoxylin and eosin slides from
the debulking surgery were retrieved from the pathology archives, and
the clinical and follow-up data were retrieved from medical records. The
pathology reports were reviewed to assess tumor sampling; when the
ovaries were small and fibrotic, they were submitted entirely. Further-
more, one section for every 1 cm of tumor was submitted for histologic
evaluation when tumors were bulky and large.
Sixty-seven patients were available for evaluation. Pathology archives
and medical records were searched for the time of initial diagnosis and
disease status at last follow-up from initial diagnosis. The end point of
recurrence-free survival (RFS) was defined as the time of recurrence. The
end point of overall survival (OS) was tumor-related death. The RFS was
calculated from the time of diagnosis to the time of recurrence. The OS
was calculated from the time of diagnosis to the time of last follow-up.
Study Design
There were two American Board–certified pathologists (P.M.F.
and F.O.) and one resident trainee in pathology (D.S.) involved in
this study. The first pathologist (P.M.F.) is a general pathologist with
12 years of experience and expertise in gynecologic pathology; the
second pathologist (F.O.) is a general pathologist with 3 years of
experience, and the third pathologist (D.S.) is a fourth-year pathology
resident. Of all the histologic changes seen after neoadjuvant therapy,
four parameters were considered for assessment, namely, fibrosis, necro-
sis, percent RT, and inflammation. Fibrosis was scored as mild (1+),
moderate (2+), and severe (3+); necrosis was scored as absent (0), 1%
to 50% (1+), and present >50 (2+); RT was scored as <5% (1+),
5% to 50% (2+), and >50% (3+); and inflammation was scored as
mild (1+) and extensive (2+) (Figures 1, A–I , 2, A–C , 3, A and B,
and 4, A and B). These grading cutoffs were chosen on the basis of
previous studies [16–18]. The grading assessment was performed on
the hematoxylin-eosin slides of the primary tumor site. The slides
were given to one pathologist at a time for scoring. Afterward, using
a multiheaded scope, the scores of each of the four parameters on
each case was reviewed, and when there was a discrepancy in scoring,
a consensus was reached.
Statistical Study
Statistical analyses were performed by R (http://www.r-project.org/).
The Cohen kappa statistic was used to measure agreement among the
three pathologists for the four histologic parameters studied (fibrosis,
Figure 2. (A) A case of ovarian carcinomawithmild fibrosis (1+) ×40,
(B) moderate fibrosis (2+) ×40, and (C) severe fibrosis (3+) ×40.
Figure 3. (A) A case of ovarian carcinoma with severe inflammation associated with tumor cells (×60). (B) A case of ovarian carcinoma
with mild inflammation association with tumor cells (×60).
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RT, necrosis, and inflammation). Kappa values were interpreted as
follows: <0.00 equals no agreement, 0 to 0.20 as slight, 0.21 to 0.40
as fair, 0.41 to 0.60 as moderate, 0.61 to 0.80 as substantial, and
0.81 to 1 as almost perfect agreement. The clinical parameters used
for modeling were age, recurrence (yes or no), tumor persistence, death
of disease (DOD), time from date of initial diagnosis to time of re-
currence, and time from first diagnosis to the time of death. To test
the association between the histologic factors and the clinical param-
eters, we performed Fisher exact test for categorical parameters and
used the logistic regression model for continuous ones. To evaluate
the association between the histologic factors and the elapsed time,
we used univariate and multivariate Cox proportional hazards models
to estimate hazard ratios that represented the correlation between rela-
tive risk of events among patients and the histologic factors. The Cox
model was also used to evaluate the association of the various combi-
nations of grading the four parameters with RFS and OS. All reported
P values were two-sided. P value was considered significant if P < .05.
Results
The clinical and pathological features of the 67 cases are summarized
in Table 1. The patient age ranged from 32 to 87 years old (median,
57 years). No recurrence was seen in 12 of 67 (17.91%) patients, 36 of
67 (53.73%) had recurrence, and 19 (28.36%) patients had persistent
disease. As for disease status at last follow-up, 23 of 67 (34.33%) were
alive with evidence of disease, 17 of 67 (25.37%) were alive with no
evidence of disease, and 27 of 67 (40.3%) were DOD. For the assess-
ment of histologic parameters, 27 of 67 (40.3%) cases showed severe
fibrosis (3+), 16 of 67 (23.88%) cases had >50% residual disease, 8 of
67 (11.94%) cases had >50% necrosis, and 31 of 67 (46.27%) cases
showed severe inflammation. The intraobserver agreement is illus-
trated in Table 2. There was substantial agreement for assessment of
“fibrosis” with a k value of 0.756, 0.713, and 0.669 for reviewers 1,
2, and 3, respectively (P < .001). There was a substantial to almost
perfect agreement for “RT” assessment with a k value of 0.867,
0.646, and 0.736 for reviewers 1, 2, and 3, respectively (P < .001).
There was almost a perfect agreement for “necrosis” assessment with
a k value of above 0.83 for all three pathologists (P < .001), and finally,
Figure 4. (A) Tumor exhibiting tumoral necrosis ≥ necrosis (2+) (×20). (B) Higher magnification shows ghost cells (×40).
Table 1. Clinical and Pathologic Features of Patients.
Characteristics
No. of evaluable patients 67
Age, year
Median 57
Range 32–87
Recurrence
N 12 (17.91)
Prog 19 (28.36)
Y 36 (53.73)
Progressive disease
Missing 34 (50.75)
N 3 (4.48)
Y 30 (44.78)
Status
Alive with evidence of disease 23 (34.33)
Alive with no evidence of disease 17 (25.37)
DOD 27 (40.3)
Fibrosis
1 24 (35.82)
2 16 (23.88)
3 27 (40.3)
RT
1 29 (43.28)
2 22 (32.84)
3 16 (23.88)
Necrosis
0 40 (59.7)
1 19 (28.36)
2 8 (11.94)
Inflammation
1 36 (53.73)
2 31 (46.27)
Data in parentheses are percentages.
Table 2. Interobserver Agreement for Each of the Four Histologic Parameters.
Pathologist Agreement k 95% CI for k P Value
Fibrosis rev1 84.1% 0.756 0.623 0.888 <.001
rev2 81.2% 0.713 0.572 0.854 <.001
rev3 78.3% 0.669 0.521 0.817 <.001
RT rev1 91.3% 0.867 0.766 0.969 <.001
rev2 76.8% 0.646 0.495 0.798 <.001
rev3 82.6% 0.736 0.601 0.872 <.001
Necrosis rev1 98.6% 0.973 0.920 1.026 <.001
rev2 91.3% 0.831 0.702 0.960 <.001
rev3 92.8% 0.859 0.740 0.978 <.001
Inflammation rev1 91.3% 0.828 0.696 0.959 <.001
rev2 84.1% 0.674 0.497 0.851 <.001
rev3 85.5% 0.713 0.548 0.877 <.001
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there was a substantial to almost perfect agreement in “inflammation”
assessment with a k value of 0.828, 0.674, and 0.713 for reviewers 1, 2,
and 3, respectively (P < .001).
The association of the four histologic parameters to RFS and OS is
shown in Table 3. Calculating from initial diagnosis, the median of
RFS was 20 months for tumors with fibrosis 3+ versus 12 months for
tumors with fibrosis 1+ and 2+ (P = .0257) (Figure 5). The median OS
from the time of diagnosis to last follow-up was 51 months for tumors
with severe fibrosis versus 32 months for tumors with mild to moderate
fibrosis (P = .0249; Figure 6). When we evaluated the association
of various combinations of the four parameters with disease outcome,
we found that tumors exhibiting (1+, 2+) fibrosis as well as (0, 1+)
necrosis seemed to have shorter RFS with P = .059 (hazard ratio [HR] =
1.921–95%, confidence interval [CI] = 0.9572–3.857) and shorter
OS with P = .0234 (HR = 2.645–95%, CI = 1.064–6.576). How-
ever, RT failed to be a significant predictive factor by itself or in any
combination with the other three parameters.
Discussion
Optimal cytoreduction (RT < 1 cm) is considered a reliable prognostic
factor in patients with advanced stage EOC treated with primary de-
bulking surgery followed by chemotherapy [14–16]. However, predic-
tive factors of disease outcome in patients treated with neoadjuvant
therapy are still lacking, and therefore, defining them will be of great
value for patient care. The morphologic alterations after neoadjuvant
chemotherapy have been uniformly seen in all tumors regardless of
types and sites. There are few data evaluating the histologic prognostic
factors of patients with EOC treated with IDS. In one study of just
18 patients, the authors were not able to find an association of morpho-
logic features including mitotic activity, volume percentage of epithelium,
mean nuclear area, and clinical response to chemotherapy as reflected by
CEA levels [6]. However, in that study, no clinical follow-up was recorded
and parameters such as fibrosis, necrosis, RT, and inflammation were not
considered. Our study is the largest and the first to address this issue.
We evaluated the most objective and reproducible morphologic
alterations (necrosis, fibrosis, inflammation, and RT) in a relatively
large series of 67 patients. In fact, when assessing intraobserver agree-
ment to define the reproducibility of our criteria among three pathol-
ogists, we found a substantial to almost perfect agreement among all
three pathologists in evaluating each of the four set histologic param-
eters (k ranged from 0.65 to 0.97). Furthermore, the assessment of
these four parameters did not vary with the pathologist’s level of expe-
rience making the evaluation of these morphologic changes very repro-
ducible. We found that stromal fibrosis was the most significant factor
in predicting disease outcome in patients diagnosed with EOC after
IDS. Patients with severe fibrosis had longer RFS (median, 20 months)
versus those with mild to moderate fibrosis (median, 12 months). In
addition, they had longer OS with median OS of 51months for tumors
with severe fibrosis versus 32 months for tumors with mild to moderate
fibrosis. Even more, patients with tumors exhibiting both mild to mod-
erate fibrosis and necrosis <50% seemed to have shorter RFS and OS
than those with severe fibrosis and >50% necrosis.
Numerous studies have looked at the association of the morphologic
changes after neoadjuvant therapy and disease outcome in various
cancer sites, including colon, esophagus, gastric, pancreas, lung, soft
tissue, and breast [7–13,19]. Therapy-induced tumor necrosis was
found to be an independent predictive factor for lower local recurrence
rate and improved OS in patients with soft tissue sarcoma [20]. How-
ever, these findings were not confirmed by another study [21]. In lung
Table 3. Association of the Histologic Parameters to RFS and OS.
RFS
P Value
HR CI OS
P Value
HR CI
Fibrosis (3 vs 1 and 2) .0257 0.4581 0.2245–0.9345 .0249 0.3806 0.1531–0.9461
Necrosis (2 vs 0 and 1) .847 1.111 0.3877–3.183 .168 0.5237 0.1968–1.393
RT (3 vs 1 and 2) .535 0.7814 0.3525–1.732 .721 0.8689 0.4027–1.875
Inflammation (2 vs 1) .804 1.089 0.5569–2.128 .385 1.4103 0.6504–3.058
Figure 5. Kaplan-Meier survival analysis revealed the association
of fibrosis with RFS. The median of RFS was 20 months for tumors
with severe fibrosis (3+) versus 12 months for tumors with mild
and moderate fibrosis (1+ and 2+; P = .0257).
Figure 6. Kaplan-Meier survival analysis revealed the association
of fibrosis with OS. The median OS from the time of diagnosis
to last follow-up was 51 months for tumors with severe fibrosis
(3+) versus 32 months for tumors with mild to moderate fibrosis
(1+ and 2+; P = .0249).
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cancer, RT < 10% was regarded as a good predictive factor for longer
term outcomes [10]. In breast cancer, histologic evidence of cyto-
toxicity, such as increased mitosis and cytoplasmic vacuolization, was
not associated with disease outcome after neoadjuvant therapy [22].
In rectal tumors, stromal fibrosis with minimal inflammatory infiltrates
was associated with reduced RFS [13,23]. Despite the controversial
data, tumor regression grading in response to preoperative adjuvant
treatment in cancers such as colorectal, exocrine pancreatic, and breast
cancers has gained acceptance by the College of American Pathologists
(CAP), which subsequently published guidelines on the matter.
Even more, and also on the basis of the CAP guidelines [24], the
recent American Joint Committee on Cancer (AJCC) staging manual
recommended the recording of tumor regression in the synoptic report
for staging colorectal and breast cancers [25]. In colorectal cancer,
tumor regression is graded in four tiers as follows: no viable tumors
(G0) as complete response, single or small groups of cells (G1) or mod-
erate response, residual cancer outgrowth by fibrosis (G2) as minimal
response, and extensive RT (G3) as poor response. In breast cancer,
the AJCC recommends defining the tumor regression as complete re-
sponse, partial response, and no response depending on the absence of
tumor, decrease in either or both T and N categories, and no apparent
changes in either T or N after chemotherapy, respectively [24,25]. Even
though the data of RT are still not definitive, the AJCC and the CAP
speculated that complete eradication of the tumor might be associated
with a better prognosis and failure to eradicate the tumor might appear
as an adverse prognostic factor, and therefore, tumor response is worth
mentioning. Thus, RT as a predictive factor for tumor response in
patients with EOC after IDS would be highly expected. However, in
our present study, RT failed to show any significant value in disease
outcome either by itself or in combination with other parameters. This
negative result might be due to the fact that our assessment of the RT
was conducted in the site of origin, the ovaries, and not in the entire
cytoreduction specimen. In addition, advanced stage ovarian cancers
are extensive and bulky tumors, making the assessment of tumor regres-
sion a very difficult task. Lastly, we did not evaluate tumor grade and
subtypes for their prognostic value because of the simple reason that
the former can change and the latter could become unrecognizable
after chemotherapy, making the evaluation impossible as already dem-
onstrated by many other investigators [5,6].
In summary, our study is the first to find that fibrosis alone and
fibrosis in combination with necrosis in ovarian cancer after neoadju-
vant therapy has impact on disease outcome. If evaluation of fibrosis
and necrosis is to be implemented in pathologic reports, it is clear that
a standardized method of assessing tumor response is required. Until
then, we propose to include histologic parameters, namely, the grade
of fibrosis and necrosis, in the final histologic report, as it could provide
an extra tool for clinicians to optimize patient management and care.
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